 - Design :Multicenter randomized controlled phase III open label trial Study subjects will be randomized to two groups in a ratio of 1:1 Subjects More than stable disease after 6 cycle 1st line of XELOX chemotherapy OR non-complete responsenon-progressive disease in cases of non-measurable disease before XELOX chemotherapy, 